Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

Just a few years ago, children with Type 1 diabetes reported to the school nurse several times a day to get a finger pricked ...

The imaging artificial intelligence developer Quibim has raised $50 million in venture capital funding, to support its work ...

All nine macaques given the control developed severe disease when exposed to bird flu, as did all given the smallest dose of ...